Abstract:Acute liver injury in the setting of acute fulminant hepatitis caused by the hepatitis B virus (HBV) can occur both during primary infection and after chronic HBV reactivation. Guidelines recommend considering antiviral therapy in both cases. Antiviral therapy with a nucleoside analog may be beneficial in patients with acute liver failure from acute HBV infection, though not all studies have shown a benefit. This is a case of a 53-year-old woman with a past medical history of untreated hepatitis C with undetectable viral load and right breast cancer status post lumpectomy, who presented to the emergency department with complaints of yellowish skin and sclera discoloration with right upper quadrant pain for one week. She was a known intravenous drug abuser and binge alcohol user. Her labs were positive for hepatitis B, hepatitis E, and hepatitis C viruses. She also had elevated liver enzymes with hyperbilirubinemia showing severe acute liver injury. Computed tomography of the abdomen and pelvis with contrast was normal, and the abdominal ultrasound showed homogenous echotexture of the liver without a focal lesion. The patient was diagnosed with acute fulminant hepatitis B. After initial hemodynamic stabilization, N-acetylcysteine (NAC) and tenofovir were started, and transaminases were followed. Liver function tests showed a downtrend, and, in a few weeks, they came to baseline. Hepatitis B viral load became undetectable as well. Acute hepatitis B infection is seldom treated. The presented case depicts the use of tenofovir in the setting of severe acute liver injury due to hepatitis B. Starting antiviral therapy (especially tenofovir disoproxil fumarate) early in the disease course was shown to have very assuring results with complete resolution of symptoms and normalization of liver function tests. The treatment protocol for acute HBV deserves further investigation.

S4396 Complexities of Managing Chronic Hepatitis B in HIV: A Case of Acute Liver Injury Post-Medication Change

Efficacy of different therapeutic modalities for patients with acute-on-chronic liver failure induced by hepatitis B

Acute-on-chronic Liver Failure in Chronic Hepatitis B: an Update.

Hepatitis B and human immunodeficiency virus coinfection

Comprehensive Treatment of Acute-On-Chronic Liver Failure in A Patient with Hepatitis B: A Case Report

Clinical Conundrum of Acute Hepatitis B With Concurrent Hepatitis E Infection Leading to Severe Acute Liver Injury

A complex case study: coexistence of multi-drug-resistant pulmonary tuberculosis, HBV-related liver failure, and disseminated cryptococcal infection in an AIDS patient

S4481 Challenges in Managing Hepatitis B Reactivation in an HIV-Positive Patient on Dialysis for End-Stage Renal Disease

Hepatitis B in the HIV-coinfected patient

HBV/HIV Coinfection: Impact on the Development and Clinical Treatment of Liver Diseases

The rate of change in clinical indicators can predict the progression of hepatitis B virus-related acute-on-chronic preliver failure

Characterization of the Circulating Microbiome in Acute-on-chronic Liver Failure Associated with Hepatitis B.

A case of successful treatment with antiretroviral therapy for HIV in a patient with marked liver dysfunction

HIV/HBV coinfection: understanding the complex interactions and their impact on spontaneous HBV clearance, chronic liver damage, cirrhosis, and hepatocellular carcinoma

Approach to the patient with chronic hepatitis B and decompensated cirrhosis

S4407 Managing Granulomatous Liver Disease in HIV/AIDS: A Case Study

Management of acute hepatitis B and reactivation of hepatitis B

Hepatitis B–Related Hepatic Flare During Immune Reconstitution Syndrome After Antiretroviral Treatment Initiation in an HBV Surface Antigen–Positive Patient With HIV: Viroimmunological and Histological Characterization

[Clinical management of patients with chronic hepatitis B virus infection]

A Fatal Outcome after Cessation of Nucleotide Analogue Therapy in a Patient with Chronic Hepatitis B: A Case Report

Host and HBV Interactions and Their Potential Impact on Clinical Outcomes